The global montelukast intermediate market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factors responsible for the growth of the market during the forecast period include an increase in demand for the montelukast intermediate from API (Active Pharmaceutical Ingredient) manufacturers, an increase in presence of generics as well as rising prevalence of asthma, bronchospasm, allergic rhinitis, and urticaria.
The montelukast intermediates are used to prevent wheezing, difficulty in breathing, chest tightness, and coughing caused by asthma. Moreover, montelukast is designated for the handling of periodic and recurrent allergic rhinitis. The important aspects pouring the market’s evolution include globally rising commonness of allergic rhinitis, urticaria, asthma, bronchospasm, burgeoning pharmaceutical industry attached with the rising call from active pharmaceutical ingredients (APIs) manufacturers, and montelukast patent expiration.
The global montelukast intermediate market analysis includes some of the key market players such as Aurobindo Pharma Ltd., Glenmark Pharmaceuticals Ltd., and Merck & Co., Inc., among others. To maintain a strong position in the market, the market players are adopting various strategic moves, such as product launches, partnerships, collaborations, and mergers and acquisitions. For instance, in November 2020, Mylan received clearance from the US Federal Trade Commission (FTC) to advance the merger of Pfizer's Upjohn generics unit.
Market Coverage
Competitive Landscape: Aurobindo Pharma Ltd., Glenmark Pharmaceuticals Ltd., and Merck & Co., Inc., among others.
Key questions addressed by the report
o Recovery Timeline
o Deviation from pre-COVID forecast
o Most affected region and segment
Global Montelukast Intermediate Market Report by Segment
By Application
• Asthma
• Allergic Rhinitis
• Bronchospasm
• Urticaria
Global Montelukast Intermediate Market by Regional Analysis
North America
Europe
Asia-Pacific
Rest of the World